Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.63
- Piotroski Score 3.00
- Grade Overweight
- Symbol (RARE)
- Company Ultragenyx Pharmaceutical Inc.
- Price $45.98
- Changes Percentage (-0.91%)
- Change -$0.42
- Day Low $45.91
- Day High $47.14
- Year High $60.37
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $103.00
- High Stock Price Target $150.00
- Low Stock Price Target $67.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$7.95
- Trailing P/E Ratio -5.21
- Forward P/E Ratio -5.21
- P/E Growth -5.21
- Net Income $-606,639,000
Income Statement
Quarterly
Annual
Latest News of RARE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Rare coin issued after California Gold Rush sold at auction for $1.4M
A rare 1870 $20 "double eagle" gold coin from Carson City, Nevada, sold for $1.44 million at a Southern California auction. Only 40-50 remain of the 3,789 produced....
By CBS News | 1 day ago -
Rare "double eagle" coin sells for $1.4 million at auction
A rare 1870 $20 "double eagle" gold coin sold for $1.44 million at a California auction. With only 40-50 known to exist, the highest-graded coin was part of the Bernard Richards collection....
By Newsweek | 1 day ago -
Rare coin issued after the California Gold Rush sold at auction for $1.4 million
A rare 1870 $20 gold coin from Carson City, Nevada, was auctioned for $1.44 million in Los Angeles. Only 40-50 of the 3,789 produced coins remain. The coin was off-market for 30 years, surprising coll...
By Yahoo! Finance | 1 day ago
